Suppr超能文献

不可切除肝细胞癌的动脉内化疗联合化疗栓塞治疗

Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.

作者信息

Colleoni M, Liessi G, Mastrapasqua G, Nelli P, Vicario G, Sgarbossa G, Pancheri F, Manente P

机构信息

Division of Medical Oncology, City Hospital, Veneto, Italy.

出版信息

Eur J Cancer. 1997 Jan;33(1):56-60. doi: 10.1016/s0959-8049(96)00307-3.

Abstract

Unresectable hepatocellular carcinoma is related to a poor prognosis. Encouraging response rates and survival have been reported with intra-arterial (i.a.) chemotherapy and chemo-embolisation, but limited data are available on the association of the two treatment modalities. We therefore started a new programme combining i.a. chemotherapy with chemo-embolisation. The treatment regimen consisted of L-leucovorin (100 mg/m2 i.v.), 5-fluorouracil (800 mg/m2 i.a.), and carboplatin (250 mg/m2 i.a.). Chemo-embolisation with mitoxantrone (10 mg/m2) plus ethiodized oil followed immediately. The same treatment plus gelatin sponge was given after 28 days. 26 patients entered the study and were evaluable for response and side-effects. Main patient characteristics were: males 21, females 5: median age 68 years (range 42-76 years); stage TNM II-III 17, IVA 9; Child's A 12, Child's B 14; elevated baseline alpha-fetoprotein 17; cirrhosis 25. 14 patients had a partial response (54%; 95% confidence interval 33-73%), 3 had stabilisation and 9 had progressive disease. Median survival was 11 months (range 2-20+). 16 patients had grade I-II pain and 15 grade I-II fever. Our results indicate that the regimen is safe, well tolerated and capable of inducing objective remissions in a high percentage of patients with hepatocellular carcinoma.

摘要

无法切除的肝细胞癌预后较差。动脉内化疗和化疗栓塞已报道有令人鼓舞的缓解率和生存率,但关于这两种治疗方式联合应用的相关数据有限。因此,我们启动了一项将动脉内化疗与化疗栓塞相结合的新项目。治疗方案包括亚叶酸钙(100mg/m²静脉注射)、5-氟尿嘧啶(800mg/m²动脉内注射)和顺铂(250mg/m²动脉内注射)。随后立即进行米托蒽醌(10mg/m²)加碘化油的化疗栓塞。28天后给予相同治疗加明胶海绵。26例患者进入研究并可评估疗效和副作用。主要患者特征为:男性21例,女性5例;中位年龄68岁(范围42-76岁);TNM分期II-III期17例,IVA期9例;Child's A级12例,Child's B级14例;基线甲胎蛋白升高17例;肝硬化25例。14例患者部分缓解(54%;95%置信区间33-73%),3例病情稳定,9例病情进展。中位生存期为11个月(范围2-20+)。16例患者有I-II级疼痛,15例有I-II级发热。我们的结果表明,该方案安全、耐受性良好,能够在高比例的肝细胞癌患者中诱导客观缓解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验